Audentes Therapeutics, Inc.

From Verify.Wiki
Jump to: navigation, search
Audentes.jpg
www.audentestx.com
Audentes Therapeutics, Inc.
Type Public
Industry Biotechnology
Founded 2012
Headquarters San Francisco, CA, United States
Key people Matthew R. Patterson (CEO), Suyash Prasad (Chief Medical Officer), John T. Gray [1]
Investors 5AM Ventures, Cormorant Asset Management, Deerfield, Foresite Capital, OrbiMed, RA Capital Management, Redmile Group, Rock Springs, Capital, Sofinnova Ventures, T. Rowe Price, Venrock, Versant Ventures [2]
Number of employees 76 [3]

Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects in the United States.
They follow that the gene therapy has powerful potential to treat these diseases through delivery of a functional copyof the affected gene to cells, resulting in production of the normal protein. [4]

Products

The products include :

  • AT132 for the treatment of X-Linked Myotubular Myopathy
  • XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome
  • Crigler-Najjar, AT982 for the treatment of Pompe disease
  • AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia
  • CASQ2-CPVT. We plan to submit Investigational New Drug applications
  • INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016

They maintain full global rights to all of our product candidates. [5]

Controversies

None Reported

Top 5 Recent Tweets

DateAuthorComment
January 31, 2021ej23ny@TedStamos @COILPOD @ThomasMarchett9 @WSBChairman @Novartis @ActiniumPharma @AstellasUS Let put it into prospective… https://t.co/pjcwNURFfH


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

  1. http://audentestx.com/company/
  2. https://www.crunchbase.com/organization/audentes-therapeutics#/entity
  3. http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103
  4. http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103#ixzz4ReMztNy0
  5. http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103#ixzz4ReNKF47T

Verification history